Reviewing the safety of erlotinib in non-small cell lung cancer

Author： Reck Martin   Mok Tony   Wolf Jürgen   Heigener David   Wu Yi-long  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.1, 2011-01, pp. : 147-157

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erlotinib in non-small cell lung cancer: a review

By Blackhall Fiona H   Rehman Shazza   Thatcher Nicholas  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 6, 2005-06 ,pp. : 995-1002

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib: a new therapeutic approach for non-small cell lung cancer

By Bonomi Philip  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 8, 2003-08 ,pp. : 1395-1401

Informa Healthcare

Access to resources Recommend Favorite

Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 85-94

Bentham Science Publishers

Access to resources Recommend Favorite

Non–Small Cell Lung Cancer

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 228-228

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Erlotinib: A Pharmacoeconomic Review of its Use in Advanced Non-Small Cell Lung Cancer

By Lyseng-Williamson Katherine A.  

PharmacoEconomics, Vol. 28, Iss. 1, 2010-01 ,pp. : 75-92

Adis International

Access to resources Recommend Favorite